Epidemiology of Colorectal Cancer (CRC) – Key Points

Global Overview

• Worldwide prevalence:
  • CRC is the 3rd most common cancer in males and the 2nd most common in females globally (WHO GLOBOCAN database).
  • Incidence and mortality are consistently higher in males than females.

United States Statistics

• Annual cases:
  • ~154,000 new cases of large bowel cancer.
    • Includes ~107,000 cases of colon cancer.
    • Includes ~47,000 cases of rectal cancer.
• Annual deaths: ~53,000 due to CRC.

Incidence

• Geographic variation:
  • Highest incidence: Australia, New Zealand, Europe, North America.
  • Lowest incidence: Africa, South-Central Asia.
  • Differences attributed to:
    • Diet and environmental exposures.
    • Socioeconomic factors.
    • Access to screening and healthcare infrastructure.
    • Genetic susceptibility.
• U.S. incidence specifics:
  • Lifetime CRC risk in average-risk individuals: ~4%.
  • Higher incidence in:
    • Males vs. females.
    • Black Americans vs. White Americans.
    • Individuals with inherited cancer syndromes (e.g., Lynch syndrome, FAP).
• Shift in tumor location:
  • Increasing cases in right-sided (proximal) colon, especially the cecum.
  • Contributing factors:
    • Better screening and removal of distal colon polyps.
    • Colonoscopy more effective in preventing left-sided CRC.
    • Right colon visualization challenges:
      • Poor preparation.
      • Incomplete colonoscopy.
      • Anatomical complexity.
• Biologic factors:
  • Right-sided CRCs often arise from sessile serrated lesions:
    • Flat, harder to detect endoscopically.
    • Often have BRAF V600E mutations.
    • Associated with microsatellite instability.
  • Suggests a true increase in cecal and ascending colon cancers.
• Trends over time:
  • U.S. incidence declined by ~2% annually, but slowed to ~1.2% per year (2014–2018).
  • Other Western countries: incidence stable or slightly increased.
  • Rapid increases seen in low-risk countries like Spain and parts of Eastern Asia and Eastern Europe.

Mortality

• Declining trends:
  • CRC mortality has declined steadily since the mid-1980s in the U.S. and other high-income nations.
  • Causes include:
    • Polyp removal.
    • Early-stage detection.
    • More effective primary and adjuvant treatments.
• Notably:
  • Mortality started declining before widespread screening or effective adjuvant therapy became routine.
• Younger adults (U.S.):
  • SEER data:
    • 2000–2004: mortality in those <50 years decreased ~2% annually
    • 2004–2018: increased by 1% per year.
    • Increase observed in White and Hispanic populations.
    • Black and Asian/Pacific Islander groups: rates stable or declined.
  • Trends confirmed by:
    • American Cancer Society.
    • National Center for Health Statistics.

Survival Rates

• United States:
  • Among the highest CRC survival rates globally.
  • Five-year survival (2011–2017, all stages and sites): ~65% (SEER data).

Global Mortality Trends

• Rising mortality in low- and middle-income countries:
  • Particularly in Central and South America and Eastern Europe.
  • Linked to:
    • Limited healthcare resources.
    • Poor access to screening and treatment.

Age and CRC Risk

• Age as a major risk factor:
  • CRC is rare before age 40.
  • Incidence increases significantly between ages 40 and 50.
  • Continues to rise with each subsequent decade.
• Screening implications:
  • Age-specific risk impacts recommendations for when and how to screen.